Over the last 13 years, Clariness has built a patient recruitment business covering 45 countries and 8 of
the top 10 pharmaceutical companies. “Clinical trials face increasing challenges in terms of cost and
timelines. Clariness strives to drive…

The German SME focuses on three technologies in the field of nanotechnology and biotechnology: tailored surface modification and encapsulation mainly by the Layer-by-Layer (LbL) technology platform; bead-based microsensors for bioanalysis; and…

Reference Number TO 32-00053

Myelo Therapeutics GmbH announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the treatment of Acute Radiation Syndrome (ARS).

Reference Number TO 32-00049

Nikolaus Rajewsky studied mathematics and physics in his hometown of Cologne. After earning his doctorate, he spent time abroad in New Jersey and New York. In 2006, the 50-year-old returned to Germany and has since been Professor of Systems Biology…

• The financing round was led by top-tier life science venture capitalists Wellington Partners and HBM Healthcare Investments, joined by existing shareholders
• The new funds will be used to execute a proof-of-concept clinical program of lead product…

Extended deadline for abstract submissions: November 28, 2018

Ipsen (Euronext: IPN; ADR: IPSEY) and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227). IPN01087 is a compound that targets cancer cells in…